What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for Bolt Biotherapeutics in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($0.36) per share for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Several other equities research analysts also recently weighed in on BOLT. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday. Stifel Nicolaus lowered their target price on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $1.13.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT opened at $0.44 on Thursday. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The firm has a 50 day moving average of $0.47 and a 200 day moving average of $0.55. Bolt Biotherapeutics has a 52 week low of $0.38 and a 52 week high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Institutional Trading of Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $26,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $27,000. Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $42,000. Finally, FMR LLC lifted its stake in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares during the period. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.